Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2007, Biogen Idec’s total revenues grew 18 percent over 2006 to almost $3.2 billion.
Currently, the company markets three major therapies and its product development pipeline includes 15 products in Phase II clinical trials and beyond. Our major products include TYSABRI® (natalizumab), the most recently approved treatment for relapsing forms of MS; AVONEX® (Interferon beta-1a), the No. 1 prescribed therapy for relapsing forms of MS worldwide; and RITUXAN® (rituximab), the world’s most prescribed therapy for non-Hodgkin’s lymphoma and marketed for the first time in 2006 for rheumatoid arthritis. AVONEX and RITUXAN have for years ranked among the top 10 biotechnology products sold globally. In recent years, we also have leveraged our core capabilities to expand development into promising new therapeutic areas, such as cardiovascular disease and hemophilia.
Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. We have additional offices in the U.S., Canada, Australia, Japan and throughout Europe.
Biogen Idec has a direct commercial presence in 25 key markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Biogen Idec attracts world-class talent to fuel its global growth, and the company currently employs more than 4,200 people worldwide.
